Combination vaccines okay for infants, study shows

Oct 03, 2007

A University of Rochester study brings relief to new parents who, while navigating a jam-packed childhood vaccine schedule, can expect to soothe their newborn through as many as 15 “pokes” by his or her six-month checkup.

The study, recently published in The Journal of Pediatrics, shows that no efficacy or safety is compromised when clinicians administer a new combination vaccine that streamlines the process – in effect, tripling up three of the recommended shots to reduce the “poke” total from five to three, at each of three bimonthly, well-child checkups.

“Only more immunizations will enter the schedule,” said Michael Pichichero, M.D., professor of Microbiology/Immunology, Pediatrics and Medicine at the University of Rochester and the study’s lead author. “Coupling or tripling of these vaccines is increasingly important, as this streamlining helps to promote parent compliance, timely vaccination and fewer administration errors.”

The study overturns findings (and fears) from a previous study that suggested problems when two specific vaccines were given at the same time – Pediarix, a combination of vaccines that guard against diphtheria, tetanus, whooping cough, hepatitis B and poliovirus, and Prevnar, which protects against 76 strains of Streptococcus pneumonia. The earlier studies found that when the vaccines were co-administered, a suboptimal immune response was produced against whooping cough, and more uncomfortable reactions, such as swelling at the injection site, could be expected.

Both Pediarix and Prevnar are recommended for administration at 2-, 4- and 6-month checkups; Prevnar was approved in 2000, shortly before the licensure of Pediarix.

“This newest study unseated both early reservations, showing that the combination vaccine was in fact just as safe and as immunogenic as separate shots, even in the midst of other vaccines in the schedule,” Pichichero said.

Study Details

A total of 575 healthy 2-month-olds were enrolled at 22 sites nationwide. Each infant was randomly assigned to one of three trial groups:

1. Combination Vaccine Group, which received three vaccines – the combination vaccine (DTaP-HepB-IPV, or brand name Pediarix), a second vaccine to protect against HiB, and a third, PCV-7 (or brand name Prevnar).

2. Separate Vaccine Group, which received five independent vaccines: DTaP, (for diphtheria, tetanus and whooping cough), HepB (for hepatitis B), IPV (for poliovirus), HiB, and PVC-7.

3. Staggered Vaccine Group that was identical to the Combination Group, save that PCV-7 vaccines were delayed by two weeks at every appointment, thereby demanding a total of six pediatric office visits, instead of three.

Blood samples were collected before the study began, and again when infants were 7 months, to test for a robust immune response to each disease-trigger.

Parents were provided a diary and asked to record temperatures, general symptoms such as fussiness, irritability or loss of appetite, and local injection site symptoms such as pain or swelling.

Results

Minor symptoms were more common in the Combination Vaccine Group; however higher fevers and more severe shot site reactions were not significantly more likely to occur in infants in any of the three groups.

For example, swelling and pain were significantly higher at the injection site of the combination vaccine, but Pichichero said that is to be expected, given that there are more ingredients in that single shot (vaccines are made from killed or modified forms of bacteria or viruses, or only pieces or products of the germs). But, he added, it was noteworthy that at no time did any local symptoms (swelling, redness, pain) lead to an infant obtaining a medical attention visit.

“Vaccine opponents may liken the process of the body processing simultaneous vaccines to a computer running too many applications; the machine grows slow, and the programs, one by one, begin to terminate,” Pichichero said. “But those fears are unfounded; we have found no evidence that a child’s body is at any point approaching a maximum threshold as far as learning to produce immune responses.”

When you administer more vaccines, you expect more symptoms, more fevers, he said. Fever, swelling, redness are all indicators that the vaccine is working, that the body is busy creating the right immunity to prevent disease.

“So long as they are mild, they pale in comparison to benefits of convenience to the parent, the fewer number of pokes to the infant, and of course, the severity of the diseases we are preventing,” he said.

Perhaps most importantly, the study showed the Combination Vaccine Group enjoyed at least as good immunogenicity as the Separate and Staggered Groups, for all criteria – including the criterion for protecting against whooping cough, for which previous, smaller-scale studies had yielded inconsistent results.

“If pediatricians were holding out on making the switch to a combined vaccine for fear that its protection might be inferior, they no longer need be concerned,” Pichichero said. “It seems the clinical relevance of any previously observed differences with regard to whooping cough immunity have been dispelled.”

Source: University of Rochester Medical Center

Explore further: Drug research and development more efficient than expected

add to favorites email to friend print save as pdf

Related Stories

Lighting up a new path for novel synthetic polio vaccine

Feb 13, 2015

Scientists from the UK and US are using technology that helped in the design of a new synthetic vaccine to combat the foot and mouth disease virus (FMDV) to now target the virus that causes polio. The synthetic ...

Quest to unravel mysteries of our gene network

Dec 18, 2014

There are roughly 27,000 genes in the human body, all but a relative few of them connected through an intricate and complex network that plays a dominant role in shaping our physiological structure and functions.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

tswogger
not rated yet Nov 01, 2007
when Pichichero says "it seems the clinical relevance of any previously observed differences with regard to whooping cough immunity have been dispelled." I'm interested to know how clinical relevance was determined....I mean whooping cough is something that affect children up until adulthood, so in order to truly study the "clinical" relevance, this study would have to follow children in both vaccine groups until adulthood and then compare rates of infection with whooping cough between groups, correct??

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.